Literature DB >> 10472780

Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases.

P Rudolph1, G MacGrogan, F Bonichon, S O Frahm, I de Mascarel, M Trojani, M Durand, A Avril, J M Coindre, R Parwaresch.   

Abstract

To evaluate the prognostic relevance of Ki-67 and topoisomerase IIalpha expression in relation to tumor stage, grade, and hormone receptor content, 942 ductal infiltrating carcinomas of the breast were examined by means of the monoclonal antibodies Ki-S11 (Ki-67) and Ki-S4 (topoisomerase IIalpha). pS2, c-erbB2, and p53 were additionally considered as prognostic variables. The median follow-up time was 149 months. Eight-hundred-and-sixty-three tumors reacted with Ki-S11 and Ki-S4; the labeling indices of the two antigens were closely associated (r = 0.93). Both correlated positively with the tumor size, c-erbB2, and p53 expression, and negatively with patient age, hormone receptor content, and pS2 immunostaining. In the univariate analysis, Ki-S11 and Ki-S4 scores, nodal status, tumor size, tumor grade, and progesterone receptor content strongly predicted both overall and metastasis-free survival (p < 0.00001). Estrogen receptor status, p53, and c-erbB2 were of minor significance. Concerning overall survival, multivariate Cox regression analysis selected a Ki-S4 score >25% (p < 0.00001) next to the nodal status, and before tumor size, progesterone receptor content, and patient age. Independent predictors of the occurrence of distant metastases were nodal status, Ki-S4, tumor size, grade 1, and progesterone receptor negativity, in that order. The Ki-S11 score was of independent prognostic significance only if examined as a continuous variable. We conclude that topoisomerase IIalpha expression as assessed by monoclonal antibody Ki-S4 may add valuable information to current prognostic models for breast cancer. Its predictive value appears to be essentially related to the proliferative activity of tumor cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10472780     DOI: 10.1023/a:1006159016703

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  18 in total

1.  Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.

Authors:  D W Stacey; M Hitomi; G Chen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Circulating tumour cells in peripheral blood: potential impact on breast cancer outcome.

Authors:  María José Serrano; José Antonio Lorente; Miguel Delgado Rodríguez; Ana Fernández; Mónica Fernández; Capilla de la Torre; Jaime Fernández Izquierdo; Pedro Sánchez Rovira
Journal:  Clin Transl Oncol       Date:  2011-03       Impact factor: 3.405

3.  Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?

Authors:  C Schindlbeck; W Janni; N Shabani; A Kornmeier; B Rack; D Rjosk; B Gerber; S Braun; H Sommer; K Friese
Journal:  J Cancer Res Clin Oncol       Date:  2005-05-11       Impact factor: 4.553

4.  PROGNOSTIC VALUE OF TOPOISOMERASE 2-ALPHA AND B-MYB IN EARLY BREAST CANCER TREATED WITH ADJUVANT CHEMOTHERAPY.

Authors:  Ljubica Radmilović Varga; Natalija Dedić Plavetić; Paula Podolski; Davor Mijatović; Ana Kulić; Damir Vrbanec
Journal:  Acta Clin Croat       Date:  2021-03       Impact factor: 0.780

5.  Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.

Authors:  Shi Yan; Jiao Shun-Chang; Chen Li; Li Jie; Lv Ya-Li; Wang Ling-Xiong
Journal:  BMC Cancer       Date:  2010-11-10       Impact factor: 4.430

6.  Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count.

Authors:  Ossama Tawfik; Bruce F Kimler; Marilyn Davis; Christopher Stasik; Sue-Min Lai; Matthew S Mayo; Fang Fan; John K Donahue; Ivan Damjanov; Patricia Thomas; Carol Connor; William R Jewell; Holly Smith; Carol J Fabian
Journal:  Virchows Arch       Date:  2007-04-26       Impact factor: 4.064

Review 7.  Prognostic value of proliferation in invasive breast cancer: a review.

Authors:  P J van Diest; E van der Wall; J P A Baak
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

8.  Prognostic Significance of p27, Ki-67, and Topoisomerase lla Expression in Clinically Nonfunctioning Pancreatic Endocrine Tumors.

Authors:  Hee Jin Chang; Kenneth P. Batts; Ricardo V. Lloyd; Thomas J. Sebo; Geoffrey B. Thompson; Christine M. Lohse; Shane V. Pankratz
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

Review 9.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.

Authors:  Elisabeth Luporsi; Fabrice André; Frédérique Spyratos; Pierre-Marie Martin; Jocelyne Jacquemier; Frédérique Penault-Llorca; Nicole Tubiana-Mathieu; Brigitte Sigal-Zafrani; Laurent Arnould; Anne Gompel; Caroline Egele; Bruno Poulet; Krishna B Clough; Hubert Crouet; Alain Fourquet; Jean-Pierre Lefranc; Carole Mathelin; Nicolas Rouyer; Daniel Serin; Marc Spielmann; Margaret Haugh; Marie-Pierre Chenard; Etienne Brain; Patricia de Cremoux; Jean-Pierre Bellocq
Journal:  Breast Cancer Res Treat       Date:  2011-11-03       Impact factor: 4.872

10.  Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts.

Authors:  Lydia Usha; Bita Tabesh; Larry E Morrison; Ruta D Rao; Kris Jacobson; April Zhu; Sanjib Basu; John S Coon
Journal:  J Hematol Oncol       Date:  2008-08-14       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.